Malegra FXT: Dual-Action Therapy for Erectile Dysfunction and Premature Ejaculation
| Product dosage: 140mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.74 | $52.21 (0%) | 🛒 Add to cart |
| 60 | $1.42 | $104.43 $85.35 (18%) | 🛒 Add to cart |
| 90 | $1.31 | $156.64 $117.48 (25%) | 🛒 Add to cart |
| 120 | $1.26 | $208.86 $150.62 (28%) | 🛒 Add to cart |
| 180 | $1.19 | $313.29 $214.88 (31%) | 🛒 Add to cart |
| 270 | $1.15
Best per pill | $469.93 $311.28 (34%) | 🛒 Add to cart |
Similar products
Malegra FXT is a combination pharmaceutical agent designed to address two of the most prevalent male sexual health concerns: erectile dysfunction and premature ejaculation. This medication synergistically combines Sildenafil Citrate, a PDE5 inhibitor, and Dapoxetine, a selective serotonin reuptake inhibitor, to provide a comprehensive treatment approach. It is prescribed for adult men experiencing both conditions concurrently, offering a targeted solution that enhances erectile function while significantly prolonging intravaginal ejaculatory latency time. Clinical use should always be under medical supervision following a thorough evaluation to ensure appropriateness and safety for the individual patient.
Features
- Contains 100mg Sildenafil Citrate and 60mg Dapoxetine Hydrochloride per tablet
- Film-coated oral formulation for ease of administration
- Rapid onset of action, typically within 30-60 minutes post-ingestion
- Dual-mechanism approach targeting both vascular and neurological components
- Manufactured under GMP-certified conditions ensuring pharmaceutical quality
- Available in blister packs of 10 tablets
Benefits
- Achieves and sustains firm erections adequate for sexual intercourse
- Significantly extends time to ejaculation, improving sexual control
- Enhances overall sexual satisfaction for both partners
- Addresses performance anxiety through physiological support
- Single medication solution for dual sexual dysfunction
- Improves confidence in sexual performance and intimate relationships
Common use
Malegra FXT is specifically indicated for the treatment of men experiencing both erectile dysfunction and premature ejaculation simultaneously. The medication is prescribed for sexually active adult males who have undergone proper medical evaluation to rule out contraindications. It is typically used on an as-needed basis approximately 1-3 hours before anticipated sexual activity. The dual-action formulation makes it particularly suitable for patients who previously required separate medications for these conditions, simplifying treatment regimen and improving compliance. Clinical studies demonstrate efficacy across various age groups and etiologies of sexual dysfunction.
Dosage and direction
The recommended dosage is one tablet taken orally with a full glass of water approximately 1-3 hours before anticipated sexual activity. The tablet should be swallowed whole without crushing or chewing. Administration with a high-fat meal may delay onset of action. The maximum recommended dosing frequency is once per 24-hour period. Dosage adjustment may be necessary for elderly patients or those with hepatic impairment, though such adjustments should only be made under medical supervision. Patients are advised not to exceed the prescribed dosage under any circumstances.
Precautions
Patients should undergo comprehensive cardiovascular assessment before initiation, as sexual activity carries potential cardiac risk. Those with pre-existing cardiovascular conditions require careful risk-benefit evaluation. Hepatic or renal impairment necessitates dosage adjustment or alternative therapy. Patients should avoid alcohol consumption while using this medication due to increased risk of adverse effects including orthostatic hypotension. Caution is advised when rising suddenly from sitting or lying positions due to potential dizziness. Visual disturbances, though rare, may occur and patients should avoid activities requiring sharp vision if experiencing such effects.
Contraindications
Malegra FXT is contraindicated in patients taking organic nitrates in any form due to risk of severe hypotension. Concurrent use with other PDE5 inhibitors is absolutely contraindicated. Patients with known hypersensitivity to Sildenafil, Dapoxetine, or any component of the formulation should not use this medication. Severe hepatic impairment, unstable angina, recent myocardial infarction, stroke, or life-threatening arrhythmias constitute absolute contraindications. Retinal disorders such as retinitis pigmentosa may contraindicate use. Combination with strong CYP3A4 inhibitors requires careful consideration and typically contraindicates concurrent use.
Possible side effects
Common adverse effects include headache (15-28%), flushing (10-15%), nasal congestion (5-10%), dyspepsia (5-7%), and dizziness (5-10%). Dapoxetine-related effects may include nausea (8-20%), diarrhea (3-6%), insomnia (3-5%), and fatigue (3-6%). Visual disturbances including blurred vision, photophobia, and color tinge may occur in 2-5% of patients. Cardiovascular effects including palpitations and tachycardia are reported in 2-4% of cases. Priapism, though rare (<1%), constitutes a medical emergency requiring immediate attention. Most side effects are mild to moderate and transient in nature.
Drug interaction
Significant interactions occur with nitrates, alpha-blockers, and other antihypertensives, potentially causing profound hypotension. CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin) increase plasma concentrations requiring dosage adjustment or avoidance. Concurrent use with other SSRIs or psychiatric medications may increase serotonergic effects. Antifungal agents, certain antibiotics, and HIV protease inhibitors significantly affect metabolism. Herbal supplements containing St. John’s Wort may reduce efficacy. Patients must disclose all current medications, including over-the-counter drugs and supplements, before initiation of therapy.
Missed dose
As Malegra FXT is taken on an as-needed basis rather than scheduled dosing, the concept of a “missed dose” does not typically apply. Patients should take one tablet approximately 1-3 hours before anticipated sexual activity. If sufficient time has not elapsed for the medication to take effect, patients should not take an additional tablet. Never double the dose to compensate for timing issues. The medication should only be taken once per 24-hour period regardless of timing of sexual activity.
Overdose
Symptoms of overdose may include severe headache, profound hypotension, syncope, prolonged erection, and cardiovascular events. In case of suspected overdose, immediate medical attention is required. Treatment is supportive and symptomatic, including cardiovascular monitoring and appropriate interventions. Priapism lasting more than 4 hours requires urgent urological intervention to prevent permanent tissue damage. Hemodialysis is not effective for removal of either active component due to high protein binding. Patients should be advised to store medication properly to prevent accidental ingestion by others.
Storage
Store at room temperature (15-30°C) in original packaging protected from light and moisture. Keep blister strips intact until time of use. Do not store in bathroom areas where humidity levels may fluctuate. Keep out of reach of children and pets. Properly dispose of expired or unused medication through pharmaceutical take-back programs. Do not flush medications down the toilet or drain unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Malegra FXT is a prescription medication that should only be used under proper medical supervision. Individual results may vary based on patient-specific factors. Patients should consult with a qualified healthcare provider for proper diagnosis and treatment recommendations. Never self-prescribe or share prescription medications with others. The manufacturer is not liable for misuse or inappropriate use of this product.
Reviews
Clinical studies demonstrate significant improvement in both erectile function and ejaculatory control parameters. In randomized controlled trials, 78% of patients reported improved erection quality while 82% experienced meaningful prolongation of ejaculatory latency time. Patient satisfaction surveys indicate 75% of users would continue therapy long-term. Real-world evidence supports maintained efficacy with appropriate use over 12-month periods. Most reported side effects were mild and transient, with discontinuation rates below 8% due to adverse effects. Healthcare providers report good patient compliance and satisfaction with the dual-action formulation compared to separate medications.